Esper Therapeutics Inc Mountain View, CA - 94041

Esper Therapeutics Inc is categorized under Commercial Biotechnical Research in Mountain View, CA and active since 2012.

Esper Therapeutics Inc was established in 2012, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.

If you are seeking more information, feel free to contact Eric Espinosa at the company’s single location by writing to 651 Franklin St Apartment 4204, Mountain View, California CA 94041 or by phoning (858) 337-8556. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Esper Therapeutics Inc
Contact Person: Eric Espinosa
Address: 651 Franklin St Apartment 4204, Mountain View, California 94041
Phone Number: (858) 337-8556
Annual Revenue (USD): $50.000 to $99.999
Founded: 2012
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Biotechnical Research
SIC Code: 8731
NAICS Code: 541711
Share This Business:

Esper Therapeutics Inc was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.

Feel free to contact Eric Espinosa for inquiries that concern Esper Therapeutics Inc by calling the company number (858) 337-8556, as your correspondence is most welcome. Additionally, the physical location of the single location of Esper Therapeutics Inc can be found at the coordinates 37.388775,-122.085317 as well as the street address 651 Franklin St Apartment 4204 in Mountain View, California 94041.

For its online presence, you may visit Esper Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.